Medovex Corporation Enters Into Second Medical Advisory Board Agreement With European Leading Spine Surgeon Dr. Karsten Ritter-Lang

ATLANTA, GA -- (Marketwired) -- 08/19/15 -- Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company has entered into a medical advisory board member consulting agreement with leading European spine surgeon Dr. Karsten Ritter-Lang.

Under the terms of the agreement, Dr. Ritter-Lang will leverage his expertise, experience and relationships in the spine treatment space, specifically the Facet Joint pain area by advising Medovex on matters related to its technology and the area of Facet Joint pain therapies. Dr. Ritter-Lang will also provide services to help introduce the Medovex's DenerveX™ System to other leading physicians and medical professionals.

Following his medical studies at The Humboldt University in Berlin, Dr. Ritter-Lang worked for the inventors of the first Artificial Disc Replacement (Katrin Buttner-Janz and Kurt Schellnack). He has been a specialist in the field of intervertebral disc prosthetics, especially in the field of abdominal approach surgery, for over 20 years. Dr. Ritter-Lang has performed almost 7,000 surgeries, of which 4,798 were spinal column reconstructions and has done over 3,500 Disc Replacement procedures using a wide range of implants both cervical and lumbar.

Dr. Ritter-Lang is one of the most respected speakers worldwide at symposiums about orthopedic surgery and neurosurgery regarding treatment using artificial intervertebral discs. His participation in the ongoing development of intervertebral disc prosthetics technology, prototypes, and implants, provides great benefits to the patients he treats. Patients come from all over the world to be treated by Dr. Ritter-Lang and his highly qualified team. Dr. Ritter-Lang is among an elite group of the most experienced Disc Replacement surgeons in the world, and has dedicated his career to the sub-specialty of Disc Replacement.

According to Manfred Sablowski, Medovex Senior Vice President of Sales and Marketing, "We are very pleased that Dr. Ritter-Lang has made the decision to accept our invitation to be a part of the DenerveX System medical advisory board. We intend to leverage both Dr. Ritter-Lang's expertise and experience as one of Europe's top spine surgeons."

Patrick Kullmann, President and COO, went on to say, "We expect his deep knowledge of the space will prove invaluable for our European launch of the DenerveX System. This addition to the advisory board along with others that will follow, coupled with our quickly emerging distribution strategy, are expected to create a powerful launch preparation and sustainment for the Medovex DenerveX System in the EU."

The Company's patented DenerveX™ System is intended to treat Facet Joint Syndrome (FJS), a condition in which the joints in the back of the spine degenerate and subsequently cause pain. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to FJS pain.

The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power generator, both designed to be less invasive with faster recovery time than current surgical treatment options. It consists of two procedures combined into one device and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit

Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


Medovex Corp.
Jason Assad
Email Contact

Source: Medovex Corporation